CSF levels of β-42 amyloid, total tau, and phospho-tau protein and apolipoprotein E were not routinely measured, such as in some other studies [43], but studies of these AD biomarkers in delirium revealed mixed results [44]. This evidence concerns the gene MAPT and Alzheimer disease.